Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 40 entries
Sorted by: Best Match Show Resources per page
[Current methods of early diagnosis of hepatic fibrosis].

Klinicheskaia meditsina

Pavlov ChS, Zolotarevskiĭ BV, Shul'pekova IuO, Kogan EA, Ivashkin VT.
PMID: 16502727
Klin Med (Mosk). 2005;83(12):58-60.

The article covers the functional and clinical significance of hepatic fibrosis. Contemporary principles of invasive and non-invasive methods of diagnostics of fibrotic alterations are described. The article also covers the main forms of fibrosis, chronic hepatic diseases in which...

Cite
Pavlov ChS, Zolotarevskiĭ BV, Shul'pekova IuO, et al. [Current methods of early diagnosis of hepatic fibrosis]. Klin Med (Mosk). 2005;83(12):58-60
Pavlov, C. h. S., Zolotarevskiĭ, B. V., Shul'pekova, I. u. O., Kogan, E. A., & Ivashkin, V. T. (2005). [Current methods of early diagnosis of hepatic fibrosis]. Klinicheskaia meditsina, 83(12), 58-60.
Pavlov, Ch S, et al. "[Current methods of early diagnosis of hepatic fibrosis]." Klinicheskaia meditsina vol. 83,12 (2005): 58-60.
Pavlov ChS, Zolotarevskiĭ BV, Shul'pekova IuO, Kogan EA, Ivashkin VT. [Current methods of early diagnosis of hepatic fibrosis]. Klin Med (Mosk). 2005;83(12):58-60. Russian. PMID: 16502727.
Copy Download .nbib Format: NLM
[Liver cirrhosis and its treatment].

Vnitrni lekarstvi

Lata J, Vanásek T, Stibůrek O.
PMID: 19785374
Vnitr Lek. 2009 Sep;55(9):774-8.

Cirrhosis is an end-stage liver disease. It is necessary to always search for the cause, attempt to initiate suitable causal treatment and assess the severity of hepatopathy by evaluating hepatic functional reserve (according to the Child-Pugh classification). It is...

Cite
Lata J, Vanásek T, Stibůrek O. Jaterní cirhóza a její lécba. [Liver cirrhosis and its treatment]. Vnitr Lek. 2009;55(9):774-8
Lata, J., Vanásek, T., & Stibůrek, O. (2009). Jaterní cirhóza a její lécba. [Liver cirrhosis and its treatment]. Vnitrni lekarstvi, 55(9), 774-8.
Lata, J, et al. "Jaterní cirhóza a její lécba." [Liver cirrhosis and its treatment]. Vnitrni lekarstvi vol. 55,9 (2009): 774-8.
Lata J, Vanásek T, Stibůrek O. Jaterní cirhóza a její lécba. [Liver cirrhosis and its treatment]. Vnitr Lek. 2009 Sep;55(9):774-8. Czech. PMID: 19785374.
Copy Download .nbib Format: NLM
[Clinical application in noninvasive diagnosis of hepatic fibrosis].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Lu LG.
PMID: 17963608
Zhonghua Gan Zang Bing Za Zhi. 2007 Oct;15(10):777-8.

No abstract available.

Cite
Lu LG. [Clinical application in noninvasive diagnosis of hepatic fibrosis]. Zhonghua Gan Zang Bing Za Zhi. 2007;15(10):777-8
Lu, L. G. (2007). [Clinical application in noninvasive diagnosis of hepatic fibrosis]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 15(10), 777-8.
Lu, Lun-gen. "[Clinical application in noninvasive diagnosis of hepatic fibrosis]." Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology vol. 15,10 (2007): 777-8.
Lu LG. [Clinical application in noninvasive diagnosis of hepatic fibrosis]. Zhonghua Gan Zang Bing Za Zhi. 2007 Oct;15(10):777-8. Chinese. PMID: 17963608.
Copy Download .nbib Format: NLM
[Recent advances in the pathogenesis, diagnosis and treatment of hepatic fibrosis].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Jia JD.
PMID: 15161496
Zhonghua Gan Zang Bing Za Zhi. 2004 May;12(5):257-8.

No abstract available.

Cite
Jia JD. [Recent advances in the pathogenesis, diagnosis and treatment of hepatic fibrosis]. Zhonghua Gan Zang Bing Za Zhi. 2004;12(5):257-8
Jia, J. D. (2004). [Recent advances in the pathogenesis, diagnosis and treatment of hepatic fibrosis]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 12(5), 257-8.
Jia, Ji-dong. "[Recent advances in the pathogenesis, diagnosis and treatment of hepatic fibrosis]." Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology vol. 12,5 (2004): 257-8.
Jia JD. [Recent advances in the pathogenesis, diagnosis and treatment of hepatic fibrosis]. Zhonghua Gan Zang Bing Za Zhi. 2004 May;12(5):257-8. Chinese. PMID: 15161496.
Copy Download .nbib Format: NLM
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group.

American journal of clinical pathology

Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Nakanuma Y, Paradis V, Quaglia A, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ.
PMID: 22180471
Am J Clin Pathol. 2012 Jan;137(1):5-9. doi: 10.1309/AJCP2T2OHTAPBTMP.

"Cirrhosis" is a morphologic term that has been used for almost 200 years to denote the end stage of a variety of chronic liver diseases. The term implies a condition with adverse prognosis due to the well-known complications of...

Cite
Hytiroglou P, Snover DC, Alves V, et al. Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol. 2012;137(1):5-9doi: 10.1309/AJCP2T2OHTAPBTMP.
Hytiroglou, P., Snover, D. C., Alves, V., Balabaud, C., Bhathal, P. S., Bioulac-Sage, P., Crawford, J. M., Dhillon, A. P., Ferrell, L., Guido, M., Nakanuma, Y., Paradis, V., Quaglia, A., Theise, N. D., Thung, S. N., Tsui, W. M., & van Leeuwen, D. J. (2012). Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. American journal of clinical pathology, 137(1), 5-9. https://doi.org/10.1309/AJCP2T2OHTAPBTMP
Hytiroglou, Prodromos, et al. "Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group." American journal of clinical pathology vol. 137,1 (2012): 5-9. doi: https://doi.org/10.1309/AJCP2T2OHTAPBTMP
Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Nakanuma Y, Paradis V, Quaglia A, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ. Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol. 2012 Jan;137(1):5-9. doi: 10.1309/AJCP2T2OHTAPBTMP. PMID: 22180471.
Copy Download .nbib Format: NLM
Should we screen for cirrhosis?.

BMJ (Clinical research ed.)

Hudson M, Sheron N, Rowe IA, Hirschfield GM.
PMID: 28701337
BMJ. 2017 Jul 12;358:j3233. doi: 10.1136/bmj.j3233.

No abstract available.

Cite
Hudson M, Sheron N, Rowe IA, et al. Should we screen for cirrhosis?. BMJ. 2017;358:j3233doi: 10.1136/bmj.j3233.
Hudson, M., Sheron, N., Rowe, I. A., & Hirschfield, G. M. (2017). Should we screen for cirrhosis?. BMJ (Clinical research ed.), 358j3233. https://doi.org/10.1136/bmj.j3233
Hudson, Mark, et al. "Should we screen for cirrhosis?." BMJ (Clinical research ed.) vol. 358 (2017): j3233. doi: https://doi.org/10.1136/bmj.j3233
Hudson M, Sheron N, Rowe IA, Hirschfield GM. Should we screen for cirrhosis?. BMJ. 2017 Jul 12;358:j3233. doi: 10.1136/bmj.j3233. PMID: 28701337.
Copy Download .nbib Format: NLM
Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis.

Gene

Wang JN, Li L, Li LY, Yan Q, Li J, Xu T.
PMID: 29944952
Gene. 2018 Oct 20;674:57-69. doi: 10.1016/j.gene.2018.06.053. Epub 2018 Jun 23.

Activation of hepatic stellate cells (HSCs) is a pivotal cellular event in liver fibrosis. Therefore, improving our understanding of the molecular pathways that are involved in these processes is essential to generate new therapies for liver fibrosis. Greater knowledge...

Cite
Wang JN, Li L, Li LY, et al. Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis. Gene. 2018;674:57-69doi: 10.1016/j.gene.2018.06.053.
Wang, J. N., Li, L., Li, L. Y., Yan, Q., Li, J., & Xu, T. (2018). Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis. Gene, 67457-69. https://doi.org/10.1016/j.gene.2018.06.053
Wang, Ji-Nian, et al. "Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis." Gene vol. 674 (2018): 57-69. doi: https://doi.org/10.1016/j.gene.2018.06.053
Wang JN, Li L, Li LY, Yan Q, Li J, Xu T. Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis. Gene. 2018 Oct 20;674:57-69. doi: 10.1016/j.gene.2018.06.053. Epub 2018 Jun 23. PMID: 29944952.
Copy Download .nbib Format: NLM
Reproducibility and limitations of transient elastography.

Liver international : official journal of the International Association for the Study of the Liver

Friedrich-Rust M, Zeuzem S.
PMID: 19413664
Liver Int. 2009 May;29(5):619-20. doi: 10.1111/j.1478-3231.2009.02032.x.

No abstract available.

Cite
Friedrich-Rust M, Zeuzem S. Reproducibility and limitations of transient elastography. Liver Int. 2009;29(5):619-20doi: 10.1111/j.1478-3231.2009.02032.x.
Friedrich-Rust, M., & Zeuzem, S. (2009). Reproducibility and limitations of transient elastography. Liver international : official journal of the International Association for the Study of the Liver, 29(5), 619-20. https://doi.org/10.1111/j.1478-3231.2009.02032.x
Friedrich-Rust, Mireen, and Zeuzem, Stefan. "Reproducibility and limitations of transient elastography." Liver international : official journal of the International Association for the Study of the Liver vol. 29,5 (2009): 619-20. doi: https://doi.org/10.1111/j.1478-3231.2009.02032.x
Friedrich-Rust M, Zeuzem S. Reproducibility and limitations of transient elastography. Liver Int. 2009 May;29(5):619-20. doi: 10.1111/j.1478-3231.2009.02032.x. PMID: 19413664.
Copy Download .nbib Format: NLM
Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection".

Annals of hepatology

Mungmunpuntipantip R, Wiwanitkit V.
PMID: 34119682
Ann Hepatol. 2021 Nov-Dec;25:100360. doi: 10.1016/j.aohep.2021.100360. Epub 2021 Jun 10.

No abstract available.

Cite
Mungmunpuntipantip R, Wiwanitkit V. Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Ann Hepatol. 2021;25:100360doi: 10.1016/j.aohep.2021.100360.
Mungmunpuntipantip, R., & Wiwanitkit, V. (2021). Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Annals of hepatology, 25100360. https://doi.org/10.1016/j.aohep.2021.100360
Mungmunpuntipantip, Rujittika, and Wiwanitkit, Viroj. "Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection"." Annals of hepatology vol. 25 (2021): 100360. doi: https://doi.org/10.1016/j.aohep.2021.100360
Mungmunpuntipantip R, Wiwanitkit V. Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Ann Hepatol. 2021 Nov-Dec;25:100360. doi: 10.1016/j.aohep.2021.100360. Epub 2021 Jun 10. PMID: 34119682; PMCID: PMC8191305.
Copy Download .nbib Format: NLM
Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection".

Annals of hepatology

Mungmunpuntipantip R, Wiwanitkit V.
PMID: 34119682
Ann Hepatol. 2021 Nov-Dec;25:100360. doi: 10.1016/j.aohep.2021.100360. Epub 2021 Jun 10.

No abstract available.

Cite
Mungmunpuntipantip R, Wiwanitkit V. Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Ann Hepatol. 2021;25:100360doi: 10.1016/j.aohep.2021.100360.
Mungmunpuntipantip, R., & Wiwanitkit, V. (2021). Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Annals of hepatology, 25100360. https://doi.org/10.1016/j.aohep.2021.100360
Mungmunpuntipantip, Rujittika, and Wiwanitkit, Viroj. "Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection"." Annals of hepatology vol. 25 (2021): 100360. doi: https://doi.org/10.1016/j.aohep.2021.100360
Mungmunpuntipantip R, Wiwanitkit V. Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Ann Hepatol. 2021 Nov-Dec;25:100360. doi: 10.1016/j.aohep.2021.100360. Epub 2021 Jun 10. PMID: 34119682; PMCID: PMC8191305.
Copy Download .nbib Format: NLM
Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection".

Annals of hepatology

Mungmunpuntipantip R, Wiwanitkit V.
PMID: 34119682
Ann Hepatol. 2021 Nov-Dec;25:100360. doi: 10.1016/j.aohep.2021.100360. Epub 2021 Jun 10.

No abstract available.

Cite
Mungmunpuntipantip R, Wiwanitkit V. Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Ann Hepatol. 2021;25:100360doi: 10.1016/j.aohep.2021.100360.
Mungmunpuntipantip, R., & Wiwanitkit, V. (2021). Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Annals of hepatology, 25100360. https://doi.org/10.1016/j.aohep.2021.100360
Mungmunpuntipantip, Rujittika, and Wiwanitkit, Viroj. "Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection"." Annals of hepatology vol. 25 (2021): 100360. doi: https://doi.org/10.1016/j.aohep.2021.100360
Mungmunpuntipantip R, Wiwanitkit V. Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection". Ann Hepatol. 2021 Nov-Dec;25:100360. doi: 10.1016/j.aohep.2021.100360. Epub 2021 Jun 10. PMID: 34119682; PMCID: PMC8191305.
Copy Download .nbib Format: NLM
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.

Zeitschrift fur Gastroenterologie

Roeb E, Geier A.
PMID: 30965381
Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 09.

Nonalcoholic fatty liver disease (NAFLD) includes nonalcoholic fatty liver (NAFL), nonalcoholic steato hepatitis (NASH) and NASH cirrhosis. NAFLD is the leading cause of liver diseases in the Western world (Central Europe, United States). The NAFLD incidence increases because of...

Cite
Roeb E, Geier A. Nichtalkoholische Steatohepatitis (NASH) – aktuelle Behandlungsempfehlungen und zukünftige Entwicklungen. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Z Gastroenterol. 2019;57(4):508-517doi: 10.1055/a-0784-8827.
Roeb, E., & Geier, A. (2019). Nichtalkoholische Steatohepatitis (NASH) – aktuelle Behandlungsempfehlungen und zukünftige Entwicklungen. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Zeitschrift fur Gastroenterologie, 57(4), 508-517. https://doi.org/10.1055/a-0784-8827
Roeb, Elke, and Geier, Andreas. "Nichtalkoholische Steatohepatitis (NASH) – aktuelle Behandlungsempfehlungen und zukünftige Entwicklungen." Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Zeitschrift fur Gastroenterologie vol. 57,4 (2019): 508-517. doi: https://doi.org/10.1055/a-0784-8827
Roeb E, Geier A. Nichtalkoholische Steatohepatitis (NASH) – aktuelle Behandlungsempfehlungen und zukünftige Entwicklungen. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 09. PMID: 30965381.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 40 entries